Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.

Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, Yu S.

Curr Med Res Opin. 2014 Nov;30(11):2223-31. doi: 10.1185/03007995.2014.941054. Epub 2014 Jul 16.

PMID:
24983744
2.

Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.

Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.

Diabetes Obes Metab. 2013 Oct;15(10):901-5. doi: 10.1111/dom.12103. Epub 2013 Apr 18.

PMID:
23531154
3.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
4.

Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.

Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM.

Am J Med Sci. 2008 Sep;336(3):241-7. doi: 10.1097/MAJ.0b013e31816250e6.

PMID:
18794619
5.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

6.

Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.

Rascati KL, Richards KM, Lopez D, Cheng LI, Wilson JP.

Clin Ther. 2011 Dec;33(12):2016-20. doi: 10.1016/j.clinthera.2011.10.018. Epub 2011 Nov 21.

PMID:
22101160
8.

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.

Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.

PLoS One. 2015 May 20;10(5):e0124287. doi: 10.1371/journal.pone.0124287. eCollection 2015.

9.
10.

Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.

Horsdal HT, Mehnert F, Rungby J, Johnsen SP.

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):717-25. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.007. Epub 2011 May 4.

PMID:
21536457
11.
12.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

13.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
14.

Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.

Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P, Ciccone G.

Eur J Endocrinol. 2013 Jun 7;169(1):117-26. doi: 10.1530/EJE-13-0299. Print 2013 Jul.

15.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.

BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.

16.
17.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
18.

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA.

BMJ. 2013 Apr 25;346:f2267. doi: 10.1136/bmj.f2267.

19.

Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL.

J Clin Endocrinol Metab. 2013 Feb;98(2):668-77. doi: 10.1210/jc.2012-3042. Epub 2013 Jan 31.

20.

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.

Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR.

Ann Intern Med. 2012 Nov 6;157(9):601-10. doi: 10.7326/0003-4819-157-9-201211060-00003.

Items per page

Supplemental Content

Write to the Help Desk